Your browser doesn't support javascript.
loading
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Raskob, Gary E; Spyropoulos, Alex C; Spiro, Theodore E; Lu, Wentao; Yuan, Zhong; Levitan, Bennett; Suh, Eunyoung; Barnathan, Elliot S.
Afiliación
  • Raskob GE; Hudson College of Public HealthUniversity of Oklahoma Health Sciences Center Oklahoma City OK.
  • Spyropoulos AC; Department of Medicine, Anticoagulation and Clinical Thrombosis Services Northwell Health at Lenox Hill HospitalThe Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institute for Medical Research New York NY.
  • Spiro TE; Department of Obstetrics and Gynecology I.M. Sechenov First Moscow State Medical University Moscow Russia.
  • Lu W; Thrombosis and Hematology Therapeutic Area Clinical Development Pharmaceuticals Bayer U.S. LLC Whippany NJ.
  • Yuan Z; Janssen Research and Development LLC Raritan NJ.
  • Levitan B; Janssen Research and Development LLC Titusville NJ.
  • Suh E; Janssen Research and Development LLC Titusville NJ.
  • Barnathan ES; Janssen Research and Development LLC Raritan NJ.
J Am Heart Assoc ; 10(22): e021579, 2021 11 16.
Article en En | MEDLINE | ID: mdl-34755519

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboembolia Venosa Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Am Heart Assoc Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboembolia Venosa Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Am Heart Assoc Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido